Andrew Orth
Net worth: 24 M $ as of 29/09/2026
Net worth: 24 M $ as of 29/09/2026
Mr. Andrew C.
Orth is a President, Chief Executive Officer & Director at City Therapeutics, Inc. He is on the Board of Directors at City Therapeutics, Inc. Mr. Orth was previously employed as a Chief Commercial Officer by Krystal Biotech, Inc. and a Senior Vice President & Head-US Busines by Alnylam Pharmaceuticals, Inc. He received his undergraduate degree from the University of Wisconsin and an MBA from Johnson Graduate School of Management.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
2.06% | 18/10/2026 | 1,063,154 ( 2.06% ) | 24 M $ | 29/09/2026 |
| Companies | Position | Start |
|---|
| Companies | Position | End |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Corporate Officer/Principal | 01/08/2023 |
| BIOGEN INC. | Corporate Officer/Principal | 31/12/2015 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Johnson Graduate School of Management
Johnson Graduate School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krystal Biotech, Inc.
Krystal Biotech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops gene therapies to patients living with debilitating diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions